Angelini inks $4.1B Catalyst buy to enter US rare disease market Leave a Comment / By Leonardo Arias / 07/05/2026 Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.
